Perjeta (Pertuzumab) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Perjeta (pertuzumab) is a targeted therapy used to treat certain types of breast cancer. It is a monoclonal antibody that binds specifically to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells in HER2-positive breast cancer.

The main forms of Perjeta (pertuzumab) are human source and animal source. Although Perjeta is a monoclonal antibody developed using recombinant DNA technology and produced in mammalian cell lines, animal-derived components may be used during the production process. Its products include monoclonal antibodies and other biologic drugs, indicated for conditions such as early breast cancer and metastatic breast cancer. Perjeta is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have impacted the perjeta market by increasing costs for monoclonal antibody production inputs, biologics manufacturing equipment, and cold-chain logistics. These pressures are most evident in hospital oncology treatment settings. North america and europe face pricing challenges due to biologics import reliance. However, tariffs are promoting localized biologic production and regional manufacturing partnerships. This enhances supply chain resilience and long-term treatment availability.

The perjeta (pertuzumab) market research report is one of a series of new reports from The Business Research Company that provides perjeta (pertuzumab) market statistics, including perjeta (pertuzumab) industry global market size, regional shares, competitors with a perjeta (pertuzumab) market share, detailed perjeta (pertuzumab) market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. This perjeta (pertuzumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The perjeta (pertuzumab) market size has grown rapidly in recent years. It will grow from $1.08 million in 2025 to $1.26 million in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to approval of her2 monoclonal antibodies, increasing breast cancer incidence, advancements in her2 diagnostics, strong clinical trial results, oncology guideline inclusion.

The perjeta (pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $2.23 million in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to growth of her2 positive patient identification, expansion into adjuvant therapy settings, increased combination regimen adoption, rising oncology drug spending, global market penetration. Major trends in the forecast period include expansion of her2 targeted combination therapies, growing use in early and metastatic breast cancer, rising adoption of dual her2 blockade, increased focus on precision oncology, improved survival outcomes in her2 positive patients.

The rising incidence of breast cancer is expected to drive the growth of the Perjeta (pertuzumab) market in the coming years. Breast cancer is a disease in which malignant cells develop in breast tissue, often originating in the ducts or lobules. The increasing prevalence of breast cancer is attributed to lifestyle factors such as higher rates of obesity and sedentary behavior, as well as improved early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy to enhance treatment outcomes. For example, in October 2023, Ray of Light Wales, a UK-based not-for-profit charity, reported that approximately 600,000 people in the UK were living after a breast cancer diagnosis, with projections indicating this number could double to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the Perjeta (pertuzumab) market.

A key trend in the Perjeta (pertuzumab) market is the development of technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies involve combining two or more drugs in a single injection administered under the skin. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative therapy combines the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing administration in just 5 to 8 minutes, significantly reducing the time required compared to traditional intravenous infusions. Phesgo is indicated for patients with advanced or recurrent HER2-positive colorectal cancer and represents the first subcutaneous option for this condition.

In June 2024, Zydus Pharmaceuticals, an India-based pharmaceutical company, partnered with Dr. Reddy's Laboratories to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India. This collaboration aims to improve affordability, availability, and patient outcomes through combined distribution efforts. Dr. Reddy's Laboratories, also based in India, manufactures pertuzumab biosimilars.

Major companies operating in the perjeta (pertuzumab) market are Roche Holding AG

North America was the largest region in the perjeta (pertuzumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the perjeta (pertuzumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Perjeta (Pertuzumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses perjeta (pertuzumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for perjeta (pertuzumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The perjeta (pertuzumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Source: Human source; Animal source
• 2) By Product: Monoclonal Antibody; Biologic Drug
• 3) By Indication: Early Breast Cancer; Metastatic Breast Cancer
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Roche Holding AG
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.